Effects of remifentanil on change of cardiac autonomic nerve system during modified electroconvulsive therapy

Effects of remifentanil on change of cardiac autonomic nerve system during modified electroconvulsive therapy - Remifentanil and modified electroconvulsive therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039271

Enrollment

Registered

2020-01-27

Start date

2020-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression and schizophrenia

Interventions

Remifentanil 0.5micrograms/kg i.v. before mECT Remifentanil 1microgams/kg i.v. before mECT Control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients scheduled to undergo mECT under general anesthesia after obtaining the written informed consent.

Exclusion criteria

Exclusion criteria: Patients with cardiovascular didease

Design outcomes

Primary

Measure	Time frame
Change of LF/HF(low-frequency/high-frequency) during mECT.	—

Countries

Japan

Contacts

Public ContactToshifumi Takasusuki

Dokkyo Medical University Department of Anesthesiology

takasusu@dokkyomed.ac.jp0282-86-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026